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Abstract—Drug delivery is one of the most common clinical
routines in hospitals, and is critical to patients’ health and
recovery. It includes a decision making process in which a
medical doctor decides the amount (dose) and frequency (dose
interval) on the basis of a set of available patients’ feature data
and the doctor’s clinical experience (a priori adaptation). This
process can be computerized in order to make the prescription
procedure in a fast, objective, inexpensive, non-invasive and
accurate way. This paper proposes a Drug Administration
Decision Support System (DADSS) to help clinicians/patients
with the initial dose computing. The system is based on a
Support Vector Machine (SVM) algorithm for estimation of
the potential drug concentration in the blood of a patient, from
which a best combination of dose and dose interval is selected
at the level of a DSS. The addition of the RANdom SAmple
Consensus (RANSAC) technique enhances the prediction accu-
racy by selecting inliers for SVM modeling. Experiments are
performed for the drug imatinib case study which shows more
than 40% improvement in the prediction accuracy compared
with previous works. An important extension to the patient
features’ data is also proposed in this paper.
Keywords-Decision Support System, Support Vector Ma-
chine, RANSAC algorithm.
I. INTRODUCTION
As medical decisions are critical to patients’ health,
the effective use of medical resources [1] and a proper
medical decision may improve the quality of health care
service. Decision Support Systems (DSSs) are computer-
based information systems that support decision-making
activities [2]. Clinical DSSs (CDSSs) form a special class
of DSSs that are designed to aid clinical decision-making
according to the characteristics of an individual patient. This
software is based on a computerized clinical knowledge or
expertise and can generate recommendations for a specific
patient [3]. When one develops a CDSS, the two main
problems that need to be addressed are: (1) the Medical
Knowledge Acquisition, which is devoted to build a medical
knowledge database in a structural way and (2) Medical
Knowledge Representation, which analyzes the data of the
medical databases in order to produce inferences helping
medical decision-making. Many tools aimed at combining
knowledge acquisition and representation were developed
in the past three decades. These tools form a class of
knowledge-based decision-support systems among which we
can name PROforma [4], Prodigy [5], EON [6], GLIF [7],
SAGE [8], Guide [9], GLARE [10] and Asbru [11], [12].
These tools approach the problem of generalization of med-
ical guidelines (GLs) representation. However, due to the
big variety of the GLs and information sources as well as
the continuous growth of the medical knowledge database
there has been no common standard for GLs representation
presented until now.
In this paper we focus on a specific class of health care
procedures, i.e. the administration of a suitable dose to a
patient based on the prediction of the blood drug concentra-
tion. The current practice of drug administration for the first
dose delivery process is mostly based on a patient’s disease
symptoms and a clinician’s empirical knowledge (a priori
adaptation). However, in some cases, e.g. when treating
HIV, cancers, etc, the effective therapeutic concentration
range is narrow, therefore the experience-based approach
creates a risk of over- or under-dosing a patient. Both
over- and under-dosing may be harmful. Hence, Therapeutic
Drug Monitoring (TDM), an approach aiming at individually
optimizing dose regimen of drug delivery based on the
measurement of the drug concentration in blood [13], is
more and more demanded in treatment procedures (either as
a routine or as a rescue method). Therefore, TDM presents a
new personalized approach in medicine. Usually, in the pro-
cess of TDM, blood measurements are carried out regularly
to check whether the prescribed dose is adequate to keep a
proper drug concentration in the human body, that is within
its therapeutic range. However, this procedure suffers from
some disadvantages such as being slow, invasive, expensive,
etc. Therefore, our work is focused on the drug’s dose
computations based on patients’ personal features (i.e. a
priori adaptation), aimed to make the TDM process faster.
The key contribution of this paper is a personalized Drug
Administration Decision Support System (DADSS) aimed
at assisting medical doctors in the daily dose computing
procedure. The system gives a personalized suggestion on
the drug’s dose and dose administration interval with respect
to different patients’ features. It is based on an enhanced ver-
sion of an SVM-based algorithm [14] that has already shown
great potential in drug concentration prediction. DADSS
consists of four phases: data inputs, data pre-processing,
analysis and clinical decision making. The core of the pre-
process phase is based on the RANdom SAmple Consensus
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(RANSAC) filtering of the initial data which is essential to
enhance the accuracy of the concentration predictions. The
analysis phase is represented by the Support Vector Machine
(SVM) algorithm that is carrying out the computation of
the results which are then analyzed in the decision phase.
The inference mechanism is built on both the knowledge
base (library) and the input data using machine learning
algorithms. DADSS can be considered as a solid brick for
any general DSS aimed at assisting medical doctors when
applying the TDM approach. For instance, it can close
the verification loop of the TAT-based medical protocol
representation [15] by bridging the modeling gap between
treatment applied to a patient and its body reaction to the
treatment.
The paper is organized as follows. Section II introduces
the related work in Decision Support System. Section III
proposes our DSS targeting drug dosing computations. Sec-
tion IV discusses a survey on the imatinib case study. Section
V draws the conclusion of this study.
II. RELATED WORK
In this section, we first discuss the current mechanisms
used in Clinical Decision Support System. Then, we talk
about some the existing DSSs of other domains based on
SVM.
A. Clinical Decision Support System
In the literature, there exist many definitions of a Deci-
sion Support System (DSS) according to various purposes,
within which Clinical DSSs (CDSSs) form a special type of
DSSs that provide clinicians with medical guidelines of best
practices in patient care according to clinical knowledge.
In the inference mechanism, computer algorithms are
applied to process the clinical data. In [16], the inference
mechanisms are divided into four categories: logic, proce-
dural, structured representations, and graph/network.
• Logic: It describes the medical knowledge using ‘true’
or ‘false’ statements. These statements can be linked to
Boolean operators such as ‘and’, ‘or’, and ‘and not’ to
form sentences.
• Procedural: It aids the diagnostic and medical decisions
by offering a ‘process’ instead of declarative facts. In
practice, due to the uncertainty in the medical domain,
it is recommended to consider both the logic signs and
the procedural knowledge. Hence, Bayes’ rule [17], etc.
have been applied to design the medical DSS.
• Structured Representations: This method emphasizes in
grouping the knowledge into well defined pieces with
higher levels of organizations. It can be used to store
both declarative and procedural medical knowledge
with or without certainty.
• Graph/Network: This includes Bayesian networks, de-
cision trees, Artificial Neural Networks (ANNs), etc.
All of them have their advantages in different aspects.
Bayesian networks are powerful in analyzing the con-
ditional independencies to predict the output; decision
trees are simple to understand and model; and ANNs
have a strong ability to ‘learn’ a model from the
observed data.
Each of the categories has its own specific application
domain.
In this paper, the proposed DSS gives a dose recommen-
dations similar to the Graph/Network category. It is based
on a drug concentration prediction method using Support
Vector Machine, a machine learning algorithm which has
successfully proved the ability to solve many classification
or regression problems.
B. Support Vector Machine based Decision Support System
Support Vector Machines (SVMs) were invented by Vap-
nik in 1979 and applied to classification and regression
problems in 1995 [18]. They use a nonlinear mapping to
transform the original training data into a higher dimensional
space, within which they search for the linear optimal
separating hyperplane, or ‘decision boundary’, to separate
the two classes. Compared with other methods such as
Neural Networks, Decision Trees, Adaptive Boosting, the
advantages of using SVM are [19], [14]:
• More accurate results due to SVM’s ability to model
complex nonlinear decision boundaries;
• Less possible to run into overfitting problems than other
methods;
• Wide application areas including prediction, classifica-
tion and regression.
Therefore, besides common areas such as object recogni-
tion, handwritten digit detection, etc, SVMs have also been
applied in decision support systems where prediction-based
decision making is required. In [19], the authors use an
SVM and an Artificial Neural Network (ANN) as bases for
their heart diseases classification DSS. The SVM was used
to separate the disease data into two classes, showing the
presence or absence of heart diseases with 80.41% accuracy.
In [20], the authors propose a Medical Diagnosis DSS with
an extension to the SVM algorithm to classify four types
of acid-base disturbance. Besides clinical cases, SVMs have
also been used in DSSs for hard landing of civil aircrafts
[21], electric power information systems [22], etc. While all
these works rely on the classification ability of SVMs, in our
paper we will present a DSS for drug administration using
SVMs for regression [23] to predict the drug concentration
in the blood and then use it to compute an appropriate dose
and a dose administration interval for a chosen patient..
III. SYSTEM DESCRIPTION
In this section, we introduce a global view of the Drug
Administration Decision Support System (DADSS) and
computational functions of the system.
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Figure 1. Flowchart of the Drug Administration Decision Support System
A. Drug Administration Decision Support System
The proposed system is composed of four main modules
as shown in Figure 1: Inputs, Preprocess, Core and Selection
parts. Input data are Library which stores the previous
patients’ feature data and New Patient features. Library is
used to build a mathematical model which links the drug
concentration to patients’ features, while the New Patient’s
data estimate the drug concentration used to generate the
final decisions on dose computation.
The Preprocess module prepares the input data for the
Core module. First of all, it checks the completion of
patient’s features. When a set of features of a new patient
is available only partially, the system replaces the missing
data by an average value to the corresponding feature data in
Library. Moreover, since each feature considered in clinical
scenarios has different absolute values in different metrics,
we normalize all the feature values using ‘zero mean, unit
variance’ technique as:
norm(feature)i =
featurei−mean(featurei)
std(featurei)
(1)
Afterwards, an effective outlier-detection technique, RAN-
dom SAmple Consensus (RANSAC) (see Section III-C), is
applied in order to enhance the accuracy of the prediction
results.
The Core module runs an SVM-based drug concentration
model using the preprocessed Library data and predicts the
concentration values for a new patient. Instead of solving a
convex quadratic programming problem (QP) as a theoreti-
cal SVM solver, DADSS simply uses a Least Square SVM
(LS-SVM) classifier to give a solution by solving a set of
linear equations [24]. In Section III-B, we give more details
about this algorithm.
The Selection module chooses the best dose and dose
intervals according to the given therapeutic ranges (possibly
one for the peak and another for the trough concentration).
However, in practice, most drugs have only one therapeutic
range available, which usually refers to the trough concen-
tration. DADSS proposes different solutions accordingly.
B. Least Square Support Vector Machine (LS-SVM)
To apply LS-SVM algorithm, we assume that there are
N patient samples in Library, some of which can be ob-
tained from the same patient, in the form of (xi,yi) ∈
{(x1,y1), · · · ,(xN ,yN)}, where yi denotes the drug concen-
tration values and x is a vector of d patient features, e.g.
age, gender, body weight, etc [14]. The goal of SVM is to
find a linear function f (x) =w ·φ(x)+b which approximates
the relationship between the dataset points and can estimate
output y according to a new input patient data. Here, φ(x)
maps the input samples to a higher-dimensional feature
space by applying a non-linear function in the original space;
w and b stand for the weights of the feature space and offset
respectively.
A loss function L (y, f (x)) = (y − f (x))2 is used to
estimate the deviations between the predicted values and
the measured ones. To minimize this loss function and
meanwhile to prevent overfitting, SVM adopts the following
objective function:
min
w,b
1
2
‖w‖2+C0
N
∑
i=1
[yi−w ·φ(xi)−b]2 (2)
where the constant C0 determines the tradeoff (relative im-
portance) between overfitting to the function and the amount
up to which deviations between the predicted and measured
values are tolerated. Note that this objective function has
an RSS (Root of Sum of Square) square fitting error and
a regularization term, which is also a standard procedure
for the training of Multi-Layer Perceptron’s (MLP) and is
related to ridge regression [25], [26]. Applying Lagrangian
analysis to solve the optimization problem of objective
function [24], [26], we see that the optimal w can always be
expressed by:
w =
N
∑
i=1
αiφ(xi) (3)
Plugging w into Equation (2), we can estimate α and b by
solving the linear system:[
K+ 1C0 I 1
1T 0
]
︸ ︷︷ ︸
H
[
α
b
]
=
[
y
0
]
(4)
where K is the kernel matrix defined by Kab = φ(xa)Tφ(xb).
The use of the kernel matrix greatly helps reducing the com-
putational complexity without explicitly computing φ(x),
making use of the fact that the SVM algorithm depends
only on dot products between sample patterns. Hence, after
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Algorithm 1 RANSAC algorithm, where data is a set of
observations, model is a model that can be fitted to data,
K is the minimum number of data points required to fit the
model parameters, M is the number of trials performed by
the algorithm, T h is a threshold determining if a data point
fits a model, and bestmodel is the model fitting the highest
number of data points.
Input: data,model,K,M,T h
Output: bestmodel
bestinliers← /0
for i = 1→M do
possibleinliers← SampleUniformly(data,K)
possiblemodel← Fit(model, possibleinliers)
inliers← /0
for all point ∈ data do
if Distance(point,model)< T h then
inliers← inliers∪{point}
end if
end for
if |inliers|> |bestinliers| then
bestinliers← inliers
end if
end for
return bestmodel← Fit(model,bestinliers)
defining the kernel function, the least-square optimization
problem could be solved simply by inverting the first term
H in the left-hand side of (4).
Once we obtain the value of α and b, the output concen-
tration of the new patient y could be then estimated through
the prediction function: f (x) = ∑Ni=1αiK(xi,x)+b.
C. RANdom SAmple Consensus Algorithm (RANSAC)
SVM-based algorithm for drug concentration prediction
has already shown a great potential in increasing the accu-
racy of the prediction [14]. However, when looking at the
training data, we have realized that some of the measure-
ments have values that lie far from the analytically predicted
value and form a set of points that we call outliers. When
assuming that the actual measurements are 100% precise
the only justification for the existence of outliers lie in the
fact that some patient profile parameters were not taken into
account. Outliers highly affect the accuracy of the SVM-
based algorithm prediction of the average drug concentration
value. Therefore, first of all we introduce the RANSAC
algorithm that filters out the outliers and can increases the
prediction precision by more than 40%.
The RANSAC [27] algorithm works as described in Al-
gorithm 1. The number of trials M is set to be big enough to
guarantee that at least one of the sets of possible inliers does
not include any outlier with a high probability p. Usually p
is set to 0.99. Let us assume, that u is the probability that
any selected data point is an inlier, then v = 1− u is the
probability of selecting an outlier. M trials of sampling each
K data points are required, where 1− p = (1− uK)M . This
implies:
M =
log(1− p)
log(1− (1−u)K) . (5)
The model of the RANSAC algorithm is a linear combi-
nation of several basis functions, such as x, x−1, x2, exp(x),
log(x), etc.. The number of basis functions corresponds
directly to the minimum number of points K required to
fit the model. The parameters of the model are the weights
of each basis function. In Section IV, a detailed introduction
of an approach to choose the basis functions is given with
respect to the threshold values.
D. Extension of Patient Features
Although the RANSAC algorithm enhances the SVM
prediction results by more than 40%, the number of used
Library samples in the Core module decreases, due to the
use of only the ‘inliers’. However, with a proper threshold
in RANSAC, we believe that the reason of causing the
outliers is the insufficiency in the patient features currently
considered in the clinical practice. Thus we extend our
algorithm such that it can account for all kinds of standard
(such as age, weight) and non-standard (not used in the
current clinical practice) patient features. In Figure 2, we
classify the dataset features into three types: Patient Profile,
Physical Measurements, and External Parameters. Patient
profile class is given by the user as semi-static data which
rarely change during the treatment. The physical measure-
ments and the external parameters are collected by using
clinical tools, questionnaires, etc..
Unfortunately, in the case study in Section IV, when
training our algorithm we depend on the available databases
that were created to support existing analytical methods
which account only for a limited number of features. Due
to a high computational complexity of the currently used
analytical methods, it would require an enormous effort
to enforce all the extra features to increase at least one
new feature, especially taking into account that it is not
clear what are the other important parameters. Applying
the SVM-based algorithm that accounts for new types of
features allows one to study a large number (several dozens)
of new parameters and determines which are the other
important ones. Choosing new valuable parameters is critical
to enhance the accuracy of the drug concentration prediction
as well as can be potentially used to enhance the existing
analytical methods. Therefore, we encourage the extension
of existing drug concentration measurements databases with
new patient profile parameters in clinical practice.
E. Selection Rules for Dose Computation
The proposed Drug Administration Decision Support Sys-
tem (DADSS) is based on the concentration prediction
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Figure 2. List of Three Groups of the Input Patients’ Feature Data
results of the new patient given by the Core module. The
final output of DADSS can be a recommended dose D∗
and/or the dose interval τ∗. Currently we account for discrete
sets of D j ∈ {100,200, · · · ,2000}mg and τ ∈ {1,2, · · · ,24}h,
because those values are more convenient for oral tablets
(as in our imatinib case study). For each value of D,
DADSS plots a Concentration-Time curve, as in Figure 3,
and chooses the best dose D∗ and τ∗ according to the given
therapeutic ranges.
As indicated before, there could be two therapeutic ranges
defined for each drug: peak and trough drug concentration
ranges. Our system enables the recommendations based
on both. Ideal peak and trough’s concentration values are
assumed to be previously defined (thanks to former clinical
trials), namely C∗p and C∗t respectively. If they are not
available, the mean values of the higher and lower bounds
of the corresponding ranges will be used as the ideal values.
However, for most drugs including imatinib, only one thera-
peutic range (generally referred to the trough concentration)
exists. DADSS can be adapted to only one therapeutic range
as well. Let us assume that the drug concentration decreases
monotonically after reaching its peak, since there are lower
and upper bounds on the trough’s therapeutic range, DADSS
defines the output τ∗ with a range (τh,τl) shown in Fig. 3
on the curve (c).
The Selection module chooses the best dose (D∗) and
range of dose interval (τh,τl) out of a cross product of
D j ∈ {100,200, · · · ,2000}mg and τ ∈ {1,2, · · · ,24}h.
• Case 1: If both peak and trough therapeutic ranges are
available. D∗ is determined as:
argmin
D j
(|C jmax −C∗p|), (6)
where C jmax stands for the peak concentration value
within 24 hours after taking the dose D j. This indicates
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Figure 3. An Example of the Drug Concentration Curves Intersecting
with the Peak and Trough Therapeutic Ranges. Curve (a)’s dose = 800mg,
Curve (b)’s dose = 600mg, Curve (c)’s dose = 400mg.
the smallest difference between the ideal peak concen-
tration value and the peak values estimated by the Core
module corresponding to each D j.
• Case 2: If only the trough therapeutic range is available.
D∗ is determined as:
argmin
D j
(|C j24 −C∗t |), (7)
where C j24 stands for the concentration values estimated
at 24 hours after giving a dose D j.
Having chosen the best dose D∗ in both cases, DADSS
computes the best τ∗ = (τh,τl). Since we want to keep
the trough drug concentration value within the trough’s
therapeutic range, τh and τl are computed according to the
higher and lower bounds of the trough’s therapeutic range
respectively.
IV. CASE STUDY
Imatinib [28], a drug used to treat chronic myeloid
leukemia and gastrointestinal stromal tumors, is the drug
considered in our case study. Until now, only a trough’s
therapeutic range of this drug has been proposed and is
presently being validated in a randomized clinical study
in leukemia patients (I-COME; ISRCTN31181395). The
trough range has a lower bound at 750mg/L, upper bound
at 1500mg/L and target value at 1000mg/L [28], [29]. To
apply our algorithm, we use the training data which include
54 patients and 252 samples in total. The testing data, in
turn, contains 65 patients presenting gastrointestinal stromal
tumors with 209 samples. The results are compared with
the general population pharmacokinetic (PK) model [30] and
the SVM-based model without RANSAC in the Preprocess
module [14]. The set of input features of patient profile data
includes: Gender, Age, Body Weight, and Type of pathology.
In the Preprocess phase, the basis of the RANSAC
algorithm is chosen to be a combination of some
typical functions: {x−2,x−1,x,x2,x3, log(x),cos(x),(1 −
exp(−x)),exp(x)}. This requires a K = 9 data points to
be randomly selected each time to compute the weights
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Table I
RANSAC BASIS FUNCTION ANALYSIS WITH RESPECT TO DIFFERENT
THRESHOLDS. TH: THRESHOLD WITH UNIT [MG/L]. SCORE 0 STANDS
FOR ‘UNUSED’ AND SCORE 1 FOR ‘IN USE’.
Th x−2 x−1 x x2 x3 log(x) cos(x) 1− exp(−x) exp(x)
250 1 0 1 0 1 1 1 1 0
500 0 0 1 0 0 1 1 0 1
1000 0 1 0 0 0 0 1 1 0
1500 0 1 0 0 0 0 0 0 0
of these basis functions. However, in our experiments,
we find that not all the listed basis functions are utilized
to estimate the inliers and the outliers. Table I shows
the utilization results (‘1’ for ‘used’, ‘0’ for ‘unused’) of
each basis function with respect to different thresholds
Th, which indicates a tolerable difference between the
measured concentration and the predicted one. In clinical
scenario, we expect that the threshold is as small as
possible to minimize the prediction inaccuracy. Therefore,
we combine the first two rows of the chosen basis functions:
f (x) = {x−2,x,x3, log(x),cos(x),(1− exp(−x)),exp(x)}.
Besides an outlier-free input data, the effectiveness and
the accuracy of the Core module highly depends on the
choice of the kernel function. In our system, we select
Gaussian distribution, a common choice with a single pa-
rameter σ , as the kernel function of the SVM algorithm.
Hence, Equation 4 has two parameters to be estimated, C0
and σ , the best combination of which is found by a grid-
search with exponentially growing sequences, e.g. {C0,σ} ∈
{10−2,10−1, · · · ,103,104}, through a 10-fold cross valida-
tion. An L-fold cross validation is a commonly-used method
to estimate the parameters of a model over each observa-
tion value [31]. It randomly partitions the original training
sample into L subsamples, of which a single subsample is
treated as the ‘validation data’ in the training phase and
the remaining L− 1 subsamples are used as training data.
The cross-validation process is then repeated L times, or
folds, to compute the values of C0 and σ with each of
the L subsamples used exactly once as the validation data.
We choose C0 and σ to be the one of the L results having
the least Mean Squared Error (MSE) between the predicted
values and the ‘validation data’.
A comparison of the prediction accuracy of our core
algorithm is shown in Figure 4 and Figure 5. Figure 4 shows
absolute values of the measured and the predicted drug
concentrations for five new patients (selected randomly from
our testing datasets). In these five sample cases, DADSS
system achieves the highest accuracy (the predicted con-
centration values are closest to the measured ones) among
the three approaches, while Pharmacokinetic (PK) method
deviates much further in most cases. Figure 5 compares the
absolute differences between the measured and the predicted
concentrations. Histograms (a) and (b) of Figure 5 show
that the PK mode and SVM without RANSAC [14] have
several samples with large differences (≥ 1000mg/L) in their
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Figure 5. Histogram Comparisons of Absolute Difference between Mea-
sured Values and Predicted Values. ((a): PK-based algorithm, (b): SVM-
based algorithm without preprocessing [14], (c): SVM-based algorithm with
preprocessing.
concentration prediction results, which was caused by the
outliers in the dataset samples. Statistically, 71% of the
predicted drug concentration values will lay within the range
of 500mg/L from the real measured values (summed number
in ’Area 1’ over the total number of patients in the test
dataset, as shown in Figure 5). While when applying the PK
model and SVM without RANSAC [14] this value will reach
only 52% and 53% respectively. On average, the proposed
system improves the mean prediction accuracy by about
44.7% over the PK model and 42.6% over SVM without
RANSAC [14].
Table II describes some examples of how the decisions
about imatinib’s dose and dose interval are made for 5 ran-
domly selected patients. For each pair of the cross product
of the dose Di and the dose interval τi for a new patient, the
Core module computes the corresponding drug concentra-
tion value. The Selection module first removes the candidate
doses whose predicted resulting drug concentration at time
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Table II
5 SAMPLE RECOMMENDATIONS FROM DADSS. M: MALE, F: FEMALE,
G: GASTROINTESTINAL STROMAL TUMORS
Patient Profile Features Recommendations
No. Gender Age Body Weight Disease D∗ τh τl
1 M 82 56kg G 400mg 13h 24h
2 F 58 53kg G 500mg 15h 24h
3 F 62 54kg G 700mg 16h 24h
4 M 58 100kg G 800mg 18h 24h
5 M 47 73kg G 500mg 14h 24h
24h (Ci24 ) are higher than the upper bound of the trough’s
therapeutic range as well as the ones whose predicted peak
concentration value is lower than the trough’s lower bound.
Furthermore, to choose the best dose, our system computes
the absolute difference between each Ci24 value and the
ideal value of the trough’s therapeutic range, and selects
the dose with respect to the smallest difference, as shown in
Equation 7. For example, for patient 1, we obtained the set of
Ci24 = [890.6,1032.5,1152.5,1239.1]mg/L that corresponds
to the set of Di = [200,400,600,800]mg. The ideal value
is 1000mg/L, therefore Ci24 = 1032.5mg/L has the smallest
difference, and thus the curve whose D∗ = 400mg is chosen.
Hereafter, the system obtains the range of the dose interval
(τ∗ = (τh,τl)) according to the lower and upper bounds of
the trough’s therapeutic range.
V. CONCLUSIONS
In this paper we have presented a Drug Administration
Decision Support System (DADSS) which aims to help
patients and doctors in the drug dose computations for
the prescription procedure. The system predicts the drug
concentrations using patient’s features and computes the
best combination of dose and dosing interval for the patient
(a priori adaptation). The main part of the system uses
Support Vector Machine (SVM)-based algorithm to model
the concentration-time curve while being trained by the
Library database. The RANSAC algorithm is applied in the
Preprocess module that enhances the prediction accuracy
about 42% with respect to SVM without RANSAC tech-
nique. Even though this approach deserves formal clinical
validation with more data sets, the case study on ima-
tinib shows an improvement by 44.7% compared with the
general PK method. We analyzed the data of 5 randomly
chosen patients and have selected the best fitting dose and
boundaries for the dose interval between two consequent
drug administrations. The system accounts for a very large
number of features which are currently not presented in the
training database. Therefore, we encourage the extension of
patient feature data sets.
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